AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

Price · $AAPGvia TradingView
AI sentiment · 7d1 articles
MAY 21net (bullish − bearish)MAY 27
Bullish
1
Neutral
0
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $AAPG in the last 30 days.

Top stories · $AAPGMore →
MAY 22·Stock TitanMed

ASCO trial sees 30% response in pediatric tumors on Ascentage combo

Ascentage Pharma (NASDAQ: AAPG) announced new clinical data from six trials presented at ASCO 2026, featuring three lead drug candidates: olverembatinib, lisaftoclax, and alrizomadlin. Highlights include a 30% objective response rate (ORR) and an 80% disease control rate (DCR) in heavily pretreated pediatric solid tumors using a combination of alrizomadlin and lisaftoclax, with a manageable safety profile. The company also reported promising results for olverembatinib in chronic myeloid leukemia (CML) and SDH-deficient tumors, with two global Phase 3 registrational trials currently enrolling patients.

MAR 24·Stock Titan

Ascentage Pharma (AAPG) director updates options and RSU holdings

Ascentage Pharma director Lu Simon Dazhong has filed an amended initial ownership report (Form 3/A) to correct inaccuracies in his previously reported equity holdings. The amendment clarifies his direct ownership of 41,457 Ordinary Shares, options over 17,965 Ordinary Shares, and 27,965 restricted share units, along with detailed vesting schedules for the options and RSUs. This filing does not represent new transactions but rather a correction of previously misstated or omitted information.

MAR 24·Stock Titan

Ascentage Pharma (AAPG) director corrects option and RSU grant details

Ascentage Pharma director Marina Bozilenko has filed an amended Form 3 to correct previously misreported details regarding her stock options and Restricted Share Units (RSUs). The amendment clarifies that her stock options cover 17,965 Ordinary Shares with an exercise price of 8.1400 per share, vesting monthly over a year starting November 26, 2025. Her RSUs, covering 27,965 Ordinary Shares, vest in four equal annual increments from November 26, 2026, to November 26, 2029, with no exercise price.

News on $AAPG

All news →